Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer

[1]  D. Groheux,et al.  The evolving role of PET/CT in breast cancer , 2010, Nuclear medicine communications.

[2]  Mithat Gonen,et al.  18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis , 2010, Journal of Nuclear Medicine.

[3]  Byung-Ho Nam,et al.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.

[4]  E. Gontier,et al.  18F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) imaging in the staging and prognosis of inflammatory breast cancer , 2009, Cancer.

[5]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[6]  C. Caldas,et al.  Triple negative breast cancers: clinical and prognostic implications. , 2009, European journal of cancer.

[7]  T. Uematsu,et al.  Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy , 2009, Breast cancer.

[8]  M. J. García-Velloso,et al.  Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer , 2009, The British journal of surgery.

[9]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[10]  D. Fuster,et al.  Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Groheux,et al.  Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  H. Tsuda,et al.  Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. , 2008, Japanese journal of clinical oncology.

[13]  A. Alavi,et al.  Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.

[14]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[15]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[16]  Masao Tanaka,et al.  Standardized Uptake Values for Breast Carcinomas Assessed by Fluorodeoxyglucose-Positron Emission Tomography Correlate with Prognostic Factors , 2007, The American surgeon.

[17]  A. Alavi,et al.  The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions , 2007, Journal of Nuclear Medicine.

[18]  T. Oyama,et al.  The relationship between FDG uptake in PET scans and biological behavior in breast cancer , 2007, Breast cancer.

[19]  P. Fumoleau,et al.  [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  M. Espié,et al.  Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen , 2007, PLoS medicine.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[22]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[23]  Charles M Perou,et al.  Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.

[24]  A. Thompson,et al.  Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[26]  A. Alavi,et al.  Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer , 2006, Breast Cancer Research and Treatment.

[27]  Sven N. Reske,et al.  Biological characterisation of breast cancer by means of PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  A. Lammertsma,et al.  18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Armoni,et al.  The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.

[30]  M. Wojtukiewicz,et al.  Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer. , 2004, Neoplasma.

[31]  T. Taguchi,et al.  Preoperative evaluation of prognosis in breast cancer patients by [18F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography , 2004, Journal of Cancer Research and Clinical Oncology.

[32]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Ellis,et al.  Expert Commentary. , 2002, Histopathology.

[34]  Torsten Mattfeldt,et al.  FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[36]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  A. Vincent-Salomon,et al.  High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases , 2000, Histopathology.

[40]  M. Schwaiger,et al.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[42]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Greco,et al.  Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation , 1998, European Journal of Nuclear Medicine.

[44]  J. Bergh,et al.  Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors , 1998, International journal of cancer.

[45]  H. Yagata,et al.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.

[46]  J E Mortimer,et al.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  P. Chappuis,et al.  A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.